文献速递前列腺癌

单次PSA检测及游离/总PSA比值与前列腺癌死亡风险的30年前瞻性队列研究

Association between one-time prostate-specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30-year prospective cohort study.
PubMed 文献 · BJU Int · 2021-05-06

该研究纳入1782名接受前列腺癌PSA筛查的男性,利用冻存血浆计算游离/总PSA比值(f/t PSA),随访30年发现基线PSA水平越高,前列腺癌死亡风险显著增加(每增加1单位PSA的HR 1.04,95%CI 1.03-1.09)。加入f/t PSA可提高模型区分度(一致性指数0.84-0.88)。PSA<1.0 ng/mL者长期死亡风险极低(1.2%),f/t PSA≥0.25可将低风险范围扩展至PSA<2.0 ng/mL(1.5%风险)。

要点

  • 基线PSA每增加1单位,30年前列腺癌死亡风险HR为1.04(95%CI 1.03-1.09)。
  • PSA<1.0 ng/mL者30年前列腺癌死亡风险仅1.2%。
  • f/t PSA≥0.25且PSA<2.0 ng/mL者风险低至1.5%,可减少或停止PSA筛查。

核心结论

  • 对于55-70岁男性,若PSA<2.0 ng/mL且f/t PSA≥0.25,可降低PSA检测频率或停止筛查。

研究设计与样本

  • 前瞻性队列研究,共纳入1782名接受前列腺癌PSA筛查的男性,随访30年,基线PSA和f/t PSA作为连续变量及按临床阈值分层进行多变量分析。

主要发现

  • 基线PSA水平越高,30年前列腺癌死亡风险显著增加,每增加1单位PSA的HR为1.04(95%CI 1.03-1.09)。
  • 加入f/t PSA可提高模型区分度,一致性指数从0.84升至0.88。
  • PSA<1.0 ng/mL男性30年前列腺癌死亡风险为1.2%。
  • f/t PSA≥0.25可将低风险范围扩展至PSA<2.0 ng/mL,该组30年死亡风险为1.5%。

关键数值与推荐

  • PSA<1.0 ng/mL:30年前列腺癌死亡风险1.2%。
  • f/t PSA≥0.25且PSA<2.0 ng/mL:30年前列腺癌死亡风险1.5%。
  • 基线PSA每增加1单位,前列腺癌死亡HR 1.04(95%CI 1.03-1.09)。

临床怎么用

  • 对55-70岁男性,可结合基线PSA和f/t PSA评估长期前列腺癌死亡风险。
  • PSA<2.0 ng/mL且f/t PSA≥0.25的男性,可考虑减少PSA检测频率或停止筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore if there is a long-term association between baseline prostate-specific antigen (PSA), including free/total PSA ratio and long-term (30-year) risk for prostate cancer death. SUBJECTS AND METHODS: In all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free to total PSA (f/t PSA). At 30-year follow-up, baseline PSA and f/t PSA were compared with recent data extracts from the Swedish Cause of Death Registry and Swedish Cancer Registry. PSA values and f/t PSA values were treated as continuous variables in a multivariable analysis and also stratified according to their distribution and useful clinical thresholds. RESULTS: Risk of death from prostate cancer after 30 years of follow-up was significantly increased with a higher baseline PSA level, with the hazard ratio being 1.04 (95% confidence interval 1.03-1.09) per increase of one unit of PSA. Adding f/t PSA increased the model's ability to discriminate (concordance index 0.84-0.88). Men with PSA levels <1.0 ng/mL had a very low long-term risk of prostate cancer death (1.2% risk). An f/t PSA ≥ 0.25 extended the low-risk range to PSA < 2.0 ng/mL (1.5% risk). CONCLUSION: Prostate-specific antigen testing can be carried out less frequently or can be discontinued in men aged 55-70 years if their PSA levels are <2.0 ng/mL and the f/t PSA is ≥0.25.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lundgren PO, Kjellman A, Norming U, et al. Association between one-time prostate-specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30-year prospective cohort study. BJU Int. 2021. PMID: 33811738. doi:10.1111/bju.15417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。